Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Sold by Weaver Consulting Group

Weaver Consulting Group cut its holdings in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 93.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,623 shares of the biotechnology company’s stock after selling 218,733 shares during the period. Weaver Consulting Group’s holdings in Brainstorm Cell Therapeutics were worth $35,000 at the end of the most recent quarter.

Separately, Armistice Capital LLC bought a new stake in shares of Brainstorm Cell Therapeutics during the 2nd quarter worth $2,680,000. Hedge funds and other institutional investors own 14.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

Brainstorm Cell Therapeutics Stock Performance

Brainstorm Cell Therapeutics stock opened at $2.23 on Wednesday. Brainstorm Cell Therapeutics Inc. has a 52 week low of $1.05 and a 52 week high of $11.89. The firm has a market capitalization of $12.72 million, a price-to-earnings ratio of -0.46 and a beta of 0.29. The company has a 50 day moving average price of $1.74 and a 200 day moving average price of $3.33.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.